PMS31 THE IMPACT OF CHANGES IN ADALIMUMAB, ETANERCEPT, AND INFLIXIMAB DOSES ON THE COSTS OF TREATING RHEUMATOID ARTHRITIS

Autor:	RK Khandker, RW Lawson, A Singh, RM Heatley, KI Johnson
Jazyk:	angličtina
Předmět:	medicine.medical_specialty business.industry Rheumatoid arthritis Health Policy medicine Adalimumab Public Health Environmental and Occupational Health medicine.disease business Dermatology Infliximab Etanercept medicine.drug
Zdroj:	Value in Health. (7):A308
ISSN:	1098-3015
DOI:	10.1016/S1098-3015(11)72184-2
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a98d04faf186d5a4d4305d0697fff4cb Zobrazit plný text záznamu